1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Phosphagenics Limited - Product Pipeline Review - 2014

Phosphagenics Limited - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 38 pages

Phosphagenics Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Phosphagenics Limited - Product Pipeline Review - 2014’, provides an overview of the Phosphagenics Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Phosphagenics Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Phosphagenics Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Phosphagenics Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Phosphagenics Limited’s pipeline products

Reasons to buy

- Evaluate Phosphagenics Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Phosphagenics Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Phosphagenics Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Phosphagenics Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Phosphagenics Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Phosphagenics Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Phosphagenics Limited - Product Pipeline Review - 2014
Table of Contents
Phosphagenics Limited Snapshot 5
Phosphagenics Limited Overview 5
Key Information 5
Key Facts 5
Phosphagenics Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Phosphagenics Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Phosphagenics Limited - Pipeline Products Glance 10
Phosphagenics Limited - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Phosphagenics Limited - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Phosphagenics Limited - Drug Profiles 14
tretinoin 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ketoconazole 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
lidocaine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
oxycodone ER 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
oxymorphone hydrochloride 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
diclofenac sodium 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Drug for Acne 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
propofol 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Proteins for Undisclosed Indication 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Phosphagenics Limited - Pipeline Analysis 25
Phosphagenics Limited - Pipeline Products by Target 25
Phosphagenics Limited - Pipeline Products by Route of Administration 26
Phosphagenics Limited - Pipeline Products by Molecule Type 27
Phosphagenics Limited - Pipeline Products by Mechanism of Action 28
Phosphagenics Limited - Recent Pipeline Updates 29
Phosphagenics Limited - Dormant Projects 32
Phosphagenics Limited - Company Statement 33
Phosphagenics Limited - Locations And Subsidiaries 36
Head Office 36
Other Locations and Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables

Phosphagenics Limited, Key Information 5
Phosphagenics Limited, Key Facts 5
Phosphagenics Limited - Pipeline by Indication, 2014 7
Phosphagenics Limited - Pipeline by Stage of Development, 2014 8
Phosphagenics Limited - Monotherapy Products in Pipeline, 2014 9
Phosphagenics Limited - Phase II, 2014 10
Phosphagenics Limited - Phase I, 2014 11
Phosphagenics Limited - Preclinical, 2014 12
Phosphagenics Limited - Discovery, 2014 13
Phosphagenics Limited - Pipeline by Target, 2014 25
Phosphagenics Limited - Pipeline by Route of Administration, 2014 26
Phosphagenics Limited - Pipeline by Molecule Type, 2014 27
Phosphagenics Limited - Pipeline Products by Mechanism of Action, 2014 28
Phosphagenics Limited - Recent Pipeline Updates, 2014 29
Phosphagenics Limited - Dormant Developmental Projects,2014 32
Phosphagenics Limited, Other Locations 36
Phosphagenics Limited, Subsidiaries 36

List of Figures

Phosphagenics Limited - Pipeline by Top 10 Indication, 2014 7
Phosphagenics Limited - Pipeline by Stage of Development, 2014 8
Phosphagenics Limited - Monotherapy Products in Pipeline, 2014 9
Phosphagenics Limited - Pipeline by Top 10 Target, 2014 25
Phosphagenics Limited - Pipeline by Top 10 Route of Administration, 2014 26
Phosphagenics Limited - Pipeline by Top 10 Molecule Type, 2014 27
Phosphagenics Limited - Pipeline Products by Top 10 Mechanism of Action, 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nociceptin Receptor (Kappa Type 3 Opioid Recepto ...

Opium (Opioid) Addiction - Pipeline Review, H2 2016

Opium (Opioid) Addiction - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Opium (Opioid) Addiction - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2016’, provides an overview of the Opium (Opioid) Addiction pipeline ...

Chronic Pain - Pipeline Review, H2 2016

Chronic Pain - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Chronic Pain - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape. The report provides ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.